Ranbaxy Malaysia Sdn. Bhd (RMSB), a subsidiary of Ranbaxy Laboratories Limited (RLL) has commissioned its new state-of-the-art manufacturing facility in Sungai Petani, Kedah, Malaysia.

According to a company release, the new plant will meet the growing demand for generic and branded medicines, in the local markets and will also position RMSB as a significant supplier of formulations for the ASEAN region.

Speaking on the occasion, Dr. Brian W. Tempest, CEO, Ranbaxy Laboratories Ltd, said, "We have had a fine tradition of providing our consumers in Malaysia and Singapore, with medicines that meet the highest standards of quality, safety, efficacy and value. I am very happy to declare this new facility open that will help to expand and consolidate our presence in the region."

The new facility is equipped with the latest technology and houses sophisticated Pre Logic Control (PLC) based process equipment that meets international specifications and conforms to GMP standards. RMSB will also be using the facility to manufacture products for supply to other Ranbaxy subsidiaries and operations within the ASEAN region.

Ranbaxy entered Malaysia in 1983, with the formation of a Joint Venture between RLL, India and Malaysian shareholders. In 1987, the Company set up a dosage forms manufacturing unit in Sungai Petani, Kedah, Malaysia, to cater to the growing needs of the local market as well as the market in Singapore. In October 2002 RMSB became a wholly owned subsidiary of RLL, India. RMSB has marketing collaborations with Schwarz Pharma (Germany), Desitin (Germany), Pharmascience (Canada), Almirall Prodesfarma (Spain), to promote their brands in Malaysia and Singapore.